New generation of drugs show early efficacy against drug-resistant TB

(Harvard Medical School) New drug regimen for multidrug-resistant tuberculosis shows early effectiveness in 85 percent of patients in a cohort including many with serious comorbidities. The results suggest a global need for expanded access to two recently developed medicines, bedaquiline and delamanid. Study cohort included many people who would have been excluded from trials because of comorbidities, severity of disease or extent of drug resistance. Findings highlight the importance of innovative regimens to improve outcomes for patients with multidrug-resistant tuberculosis.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Tuberculosis (TB) caused by the pathogenic agent of Mycobacterium tuberculosis (Mtb), remains a major global health threat. There were approximate 10 million new TB cases and 1.40 million deaths in the world in 2018 (World Health Organization, 2019). Moreover, about half a million of new cases were rifampicin-resistant TB, of which 78% had multidrug-resistant (MDR) TB (World Health Organization, 2019). Although the treatment success rate can reach up to 85% after standard 2HRZE/4HR (a 2-month intensive phase of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by a 4-month continuation phase of ri...
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
In conclusion, our results demonstrated that flunarizine enhanced the bactericidal ability of macrophages and clarified its CaM-pCAMKII-dependent mechanism. Therefore, our findings strongly support further studies of this currently approved drug as an HDT candidate for TB therapy.PMID:34533236 | DOI:10.1002/JLB.4A0221-119RR
Source: Journal of Leukocyte Biology - Category: Hematology Authors: Source Type: research
Drug-resistant tuberculosis (DR-TB) remains a major public health concern worldwide. Bedaquiline, a novel diarylquinoline, was added to the WHO-recommended all-oral regimen for patients with multidrug-resistan...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are a major public health threat because of reduced treatment options and poor patient outcomes. New antimicrobials and regimens have been developed in recent years, but their effectiveness has been hampered by the rise and spread of drug-resistant strains. Whole genome sequencing (WGS) has emerged as a tool able to revolutionise TB surveillance and the clinical management of TB. This approach is now widely used by public health agencies in detecting outbreaks and transmission chains, thus supporting the formulation of evidence-based health po...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
BJOG. 2021 Sep 15. doi: 10.1111/1471-0528.16872. Online ahead of print.NO ABSTRACTPMID:34524715 | DOI:10.1111/1471-0528.16872
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research
[WHO-AFRO] The Green Light Committee (GLC) Initiative, together with the Working Group on MDR-TB, promotes implementation of the component two of the Stop TB Strategy that calls for the control and prevention of multidrug-resistant tuberculosis (MDR-TB) through: (i) increased access to quality-assured second-line anti-TB drugs; and (ii) prevention of development of resistance to anti-TB drugs in accordance with the Global Plan to Stop TB (2006-2015) and the Global MDR/XDR-TB Response plan (2007-2008).
Source: AllAfrica News: Tuberculosis - Category: Infectious Diseases Source Type: news
Antimicrob Agents Chemother. 2021 Sep 13:AAC0154521. doi: 10.1128/AAC.01545-21. Online ahead of print.ABSTRACTMycobacterium abscessus lung disease is difficult to treat due to intrinsic drug resistance and the persistence of drug-tolerant bacteria. Currently, the standard of care is a multi-drug regimen with at least 3 active drugs, preferably including a β-lactam (imipenem or cefoxitin). These regimens are lengthy, toxic, and have limited efficacy. The search for more efficacious regimens led us to evaluate bedaquiline, a diarylquinoline licensed for treatment of multidrug-resistant tuberculosis. We performed in vitr...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Source Type: research
ConclusionsThis high prevalence of slow metabolizers for isoniazid in the Peruvian population should be further studied and considered to help individualize drug regimens, especially in countries with a great genetic diversity like Peru. These data will help the Peruvian National Tuberculosis Control Program develop new strategies for therapies.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conditions:   Pre-Extensively Drug-Resistant Pulmonary TB;   Treatment Intolerant Multidrug-Resistant Pulmonary TB;   Non-responsive Multidrug-Resistant Pulmonary TB Interventions:   Drug: Linezolid;   Drug: Bedaquiline;   Drug: Pretomanid Sponsors:   Tuberculosis Research Centre, India;   International Union Against Tuberculosis and Lung Diseases;   Sarvodaya Charitable Trust Hospital, Ghatkopar, Mumbai;   Shatabdi Centenary Hospital, Govandi, Mumbai;   KGMU, Lucknow;   SN M...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bedaquiline | Harvard | International Medicine & Public Health | Multidrug Resistance | Study | Tuberculosis